![]()
Gene-Chemical Interaction Annotations Click to see Annotation Detail View
Term | Qualifier | Evidence | With | Reference | Notes | Source | Original Reference(s) | 17alpha-ethynylestradiol | increases expression | ISO | RGD:1322329 | 6480464 | Ethinyl Estradiol results in increased expression of FEZF2 mRNA | CTD | PMID:17942748 | 2,3,7,8-tetrachlorodibenzodioxine | increases expression | EXP | | 6480464 | Tetrachlorodibenzodioxin results in increased expression of FEZF2 mRNA | CTD | PMID:32109520 | 4,4'-sulfonyldiphenol | affects expression | ISO | RGD:1322329 | 6480464 | bis(4-hydroxyphenyl)sulfone affects the expression of FEZF2 mRNA | CTD | PMID:30951980 | 6-propyl-2-thiouracil | increases expression | EXP | | 6480464 | Propylthiouracil results in increased expression of FEZF2 mRNA | CTD | PMID:24780913 | aflatoxin B1 | decreases methylation | ISO | RGD:1346685 | 6480464 | Aflatoxin B1 results in decreased methylation of FEZF2 gene | CTD | PMID:27153756 | all-trans-retinoic acid | decreases expression | ISO | RGD:1346685 | 6480464 | Tretinoin results in decreased expression of FEZF2 mRNA | CTD | PMID:21934132 | arsane | increases methylation | ISO | RGD:1346685 | 6480464 | Arsenic results in increased methylation of FEZF2 gene | CTD | PMID:24525453 | arsenic atom | increases methylation | ISO | RGD:1346685 | 6480464 | Arsenic results in increased methylation of FEZF2 gene | CTD | PMID:24525453 | arsenite(3-) | increases methylation | ISO | RGD:1346685 | 6480464 | arsenite results in increased methylation of FEZF2 promoter | CTD | PMID:23974009 | benzo[a]pyrene | affects methylation | ISO | RGD:1346685 | 6480464 | Benzo(a)pyrene affects the methylation of FEZF2 promoter | CTD | PMID:27901495 | benzo[a]pyrene | increases methylation | ISO | RGD:1346685 | 6480464 | Benzo(a)pyrene results in increased methylation of FEZF2 5' UTR | CTD | PMID:27901495 | bis(2-ethylhexyl) phthalate | decreases expression | ISO | RGD:1346685 | 6480464 | Diethylhexyl Phthalate results in decreased expression of FEZF2 mRNA | CTD | PMID:31163220 | bisphenol A | decreases expression | EXP | | 6480464 | bisphenol A results in decreased expression of FEZF2 mRNA | CTD | PMID:25181051 | bisphenol A | multiple interactions | ISO | RGD:1346685 | 6480464 | [bisphenol A co-treated with Fulvestrant] results in decreased methylation of FEZF2 gene | CTD | PMID:31601247 | bisphenol A | decreases methylation | ISO | RGD:1346685 | 6480464 | bisphenol A results in decreased methylation of FEZF2 gene | CTD | PMID:31601247 | bisphenol A | increases expression | EXP | | 6480464 | bisphenol A results in increased expression of FEZF2 mRNA | CTD | PMID:30816183, PMID:34947998 | bisphenol A | decreases expression | ISO | RGD:1322329 | 6480464 | bisphenol A results in decreased expression of FEZF2 mRNA | CTD | PMID:30951980, PMID:32156529 | bisphenol A | increases methylation | EXP | | 6480464 | bisphenol A results in increased methylation of FEZF2 gene | CTD | PMID:28505145 | bisphenol F | affects expression | ISO | RGD:1322329 | 6480464 | bisphenol F affects the expression of FEZF2 mRNA | CTD | PMID:30951980 | cadmium dichloride | decreases methylation | EXP | | 6480464 | Cadmium Chloride results in decreased methylation of FEZF2 promoter | CTD | PMID:22457795 | choline | multiple interactions | ISO | RGD:1322329 | 6480464 | [Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in decreased methylation of FEZF2 gene | CTD | PMID:20938992 | clofibrate | increases expression | ISO | RGD:1322329 | 6480464 | Clofibrate results in increased expression of FEZF2 mRNA | CTD | PMID:17585979 | Cuprizon | decreases expression | EXP | | 6480464 | Cuprizone results in decreased expression of FEZF2 mRNA | CTD | PMID:26577399 | dorsomorphin | multiple interactions | ISO | RGD:1346685 | 6480464 | [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1 more ... | CTD | PMID:27188386 | entinostat | multiple interactions | ISO | RGD:1346685 | 6480464 | [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FEZF2 mRNA | CTD | PMID:27188386 | entinostat | decreases expression | ISO | RGD:1346685 | 6480464 | entinostat results in decreased expression of FEZF2 mRNA | CTD | PMID:26272509 | fenthion | increases expression | ISO | RGD:1322329 | 6480464 | Fenthion results in increased expression of FEZF2 mRNA | CTD | PMID:34813904 | fenvalerate | increases expression | EXP | | 6480464 | fenvalerate results in increased expression of FEZF2 mRNA | CTD | PMID:30307764 | folic acid | multiple interactions | ISO | RGD:1322329 | 6480464 | [Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in decreased methylation of FEZF2 gene | CTD | PMID:20938992 | folic acid | increases expression | ISO | RGD:1322329 | 6480464 | Folic Acid results in increased expression of FEZF2 mRNA | CTD | PMID:25629700 | fulvestrant | multiple interactions | ISO | RGD:1346685 | 6480464 | [bisphenol A co-treated with Fulvestrant] results in decreased methylation of FEZF2 gene | CTD | PMID:31601247 | L-methionine | multiple interactions | ISO | RGD:1322329 | 6480464 | [Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in decreased methylation of FEZF2 gene | CTD | PMID:20938992 | mercury dibromide | decreases expression | ISO | RGD:1346685 | 6480464 | mercuric bromide results in decreased expression of FEZF2 mRNA | CTD | PMID:26272509 | mercury dibromide | multiple interactions | ISO | RGD:1346685 | 6480464 | [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FEZF2 mRNA | CTD | PMID:27188386 | methylmercury chloride | affects expression | ISO | RGD:1322329 | 6480464 | methylmercuric chloride affects the expression of FEZF2 mRNA | CTD | PMID:21613230 | methylmercury chloride | decreases expression | ISO | RGD:1346685 | 6480464 | methylmercuric chloride results in decreased expression of FEZF2 mRNA | CTD | PMID:28001369 | p-chloromercuribenzoic acid | decreases expression | ISO | RGD:1346685 | 6480464 | p-Chloromercuribenzoic Acid results in decreased expression of FEZF2 mRNA | CTD | PMID:26272509 | p-chloromercuribenzoic acid | multiple interactions | ISO | RGD:1346685 | 6480464 | [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FEZF2 mRNA | CTD | PMID:27188386 | panobinostat | decreases expression | ISO | RGD:1346685 | 6480464 | panobinostat results in decreased expression of FEZF2 mRNA | CTD | PMID:26272509 | panobinostat | multiple interactions | ISO | RGD:1346685 | 6480464 | [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FEZF2 mRNA | CTD | PMID:27188386 | phenylmercury acetate | decreases expression | ISO | RGD:1346685 | 6480464 | Phenylmercuric Acetate results in decreased expression of FEZF2 mRNA | CTD | PMID:26272509 | phenylmercury acetate | multiple interactions | ISO | RGD:1346685 | 6480464 | [NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FEZF2 mRNA | CTD | PMID:27188386 | potassium dichromate | increases expression | ISO | RGD:1322329 | 6480464 | Potassium Dichromate results in increased expression of FEZF2 mRNA | CTD | PMID:23608068 | resveratrol | multiple interactions | ISO | RGD:1346685 | 6480464 | [Plant Extracts co-treated with Resveratrol] results in decreased expression of FEZF2 mRNA | CTD | PMID:23557933 | SB 431542 | multiple interactions | ISO | RGD:1346685 | 6480464 | [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1 more ... | CTD | PMID:27188386 | silver atom | decreases expression | ISO | RGD:1346685 | 6480464 | Silver results in decreased expression of FEZF2 mRNA | CTD | PMID:26551752 | silver(0) | decreases expression | ISO | RGD:1346685 | 6480464 | Silver results in decreased expression of FEZF2 mRNA | CTD | PMID:26551752 | Soman | increases expression | EXP | | 6480464 | Soman results in increased expression of FEZF2 mRNA | CTD | PMID:19281266 | tetracycline | increases expression | ISO | RGD:1322329 | 6480464 | Tetracycline results in increased expression of FEZF2 mRNA | CTD | PMID:16917069 | trichostatin A | decreases expression | ISO | RGD:1346685 | 6480464 | trichostatin A results in decreased expression of FEZF2 mRNA | CTD | PMID:24935251, PMID:26272509 | trichostatin A | multiple interactions | ISO | RGD:1346685 | 6480464 | [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FEZF2 mRNA | CTD | PMID:27188386 | valproic acid | affects expression | ISO | RGD:1346685 | 6480464 | Valproic Acid affects the expression of FEZF2 mRNA | CTD | PMID:25979313 | valproic acid | multiple interactions | ISO | RGD:1346685 | 6480464 | [NOG protein co-treated with Valproic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FEZF2 mRNA | CTD | PMID:27188386 | valproic acid | decreases expression | ISO | RGD:1322329 | 6480464 | Valproic Acid results in decreased expression of FEZF2 mRNA | CTD | PMID:24896083 | valproic acid | decreases expression | ISO | RGD:1346685 | 6480464 | Valproic Acid results in decreased expression of FEZF2 mRNA | CTD | PMID:23179753 more ... | vorinostat | multiple interactions | ISO | RGD:1346685 | 6480464 | [NOG protein co-treated with Vorinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FEZF2 mRNA | CTD | PMID:27188386 | vorinostat | decreases expression | ISO | RGD:1346685 | 6480464 | vorinostat results in decreased expression of FEZF2 mRNA | CTD | PMID:26272509 | |